A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Clinical trial NCT04298606 · COMPLETED

Trial details

NCT number: NCT04298606
Sponsor: Roswell Park Cancer Institute
Status: COMPLETED
Phase: Early Phase 1
Study type: INTERVENTIONAL

Chronic Obstructive Pulmonary Disease Lung Non-Small Cell Carcinoma Pneumonia Stage IB Lung Cancer AJCC v8 Stage II Lung Cancer AJCC v8 Stage IIA Lung Cancer AJCC v8 Stage IIB Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8

Start date: 2021-11-22
Primary completion: 2025-12-05
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.